Photonify Technologies Names Robin L. Bush Vice President of Quality, Regulatory and Clinical Affairs

Photonify Technologies Names Robin L. Bush Vice President of Quality, Regulatory and Clinical Affair. Company history included.

FREMONT, California, Feb. 28, 2002 ¡V Photonify Technologies, Inc. a developer of a novel non-invasive medical imaging technology, today announced that Robin L. Bush has joined the company as Vice President of Quality, Regulatory and Clinical Affairs.
Ms. Bush brings over 22 years experience in the medical device industry, establishing and managing regulatory affairs, quality assurance, clinical trials and compliance functions. Most recently, she was Vice President of Regulatory Affairs, Clinical Affairs, and Quality Assurance at Artemis Medical.
¡§We are thrilled to have Robin join Photonify, she brings a wealth of knowledge and experience that will be critical in our next phase of development.¡¨ commented Mohamed Elmandjra, President and CEO.
She served in a similar capacity at VidaMed from July 1997 to July 2000. From 1998 to 1997, Ms. Bush was Director of Regulatory Affairs and Quality Assurance for Aesculap, Inc., a manufacturer of medical instruments. From 1979-1988, Ms. Bush worked at Collagen Corporation in regulatory and quality assurance. She has worked successfully with the FDA to conduct clinical trials, and gain regulatory approvals for many products that are marketed in the surgical specialties of breast cancer, urology, neurosurgery, orthopedics, spinal, general surgery, plastic surgery, dermatology and dental surgery.
¡§I am excited about my new role at Photonify and look forward to driving the technology to maximize clinical value and build strong regulatory and quality processes.¡¨ Ms. Bush said. She is a certified Regulatory Affairs Professional (RAC) and holds a B.A. in Human Biology and Psychology from Stanford University and an MBA from Golden Gate University.
About Photonify Technologies
Founded in November 1999, Photonify Technologies is a privately held company leading the development of new medical technologies based on Diffused Optical Imaging and Spectroscopy (DOIS) technology. Driven by the advancement of the modern laser technologies and some fundamental breakthroughs, the founders, from Harvard Medical School and MIT sought to develop a technology that makes it possible to provide non-invasive imaging of specific physiological characteristics of human tissues. Since its founding, Photonify has secured funds from BioAsia Investments, Trident Investments and other investors.